Topics:

Ovarian Cancer

This article discusses the discovery and biologic significance of HE4 and evaluates available evidence regarding the utility of HE4 as a biomarker for ovarian and endometrial cancer.

Ovarian Cancer

The Society of Gynecologic Oncology (SGO) recently issued two new clinical practice statements recommending genetic testing for all women with endometrial and ovarian cancers, regardless of family history.

Being overweight increases a woman’s risk of ovarian cancer, according to a new comprehensive report. The finding offers a way to reduce the risk.

A new study found that high concentrations of vitamin C increased the effectiveness of chemotherapy in an ovarian cancer mouse model. A high-dose delivery of the vitamin also resulted in lesser toxicity from chemotherapy in cancer patients.

The use of oral contraceptives in women with BRCA1/2 mutations was associated with a reduced risk of ovarian cancer.

With regard to potential research strategies relevant to the treatment of triple-negative breast cancer/basal-like breast cancer, potential targets include PTEN, INPP4B, PIK3CA, KRAS, BRAF, EGFR, FGFR1, FGFR2, IGFR1, KIT, MET, PDGFRA, and the HIF1-α/ARNT pathway. Many of these will be discussed further in this review article.

The use of an enhanced recovery pathway for perioperative care in complex gynecological surgery can reduce length of hospital stay, need for narcotic pain control, and costs.

A new index using protein markers can identify ovarian cancer cases at high and low risk for recurrence and discriminate between short- and long-term survivors.

Pages

Subscribe to
Please Wait 20 seconds or click here to close